Tetranectin as a Potential Biomarker for Stable Coronary Artery Disease

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Chen, Yanjia ^a   Han, Hui ^a   Yan, Xiaoxiang ^a   Ding, Fenghua ^a   Su, Xiuxiu ^a   Wang, Haibo ^a   Chen, Qiujing ^a   Lu, Lin ^a   Zhang, Ruiyan ^a   Jin, Wei ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; LECTIN; TETRANECTIN;

AGED; BLOOD; CORONARY ARTERY DISEASE; CORONARY BLOOD VESSEL; CROSS-SECTIONAL STUDY; FEMALE; GENE EXPRESSION REGULATION; HUMAN; MALE; METABOLISM; MIDDLE AGED;

AGED; BIOMARKERS; CORONARY ARTERY DISEASE; CORONARY VESSELS; CROSS-SECTIONAL STUDIES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LECTINS, C-TYPE; MALE; MIDDLE AGED;

EID: 84949204660     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep17632     Document Type: Article

References (27)

1. Forouzanfar, M. H. et al. Assessing the global burden of ischemic heart disease, part 2: analytic methods and estimates of the global epidemiology of ischemic heart disease in 2010. Glob Heart 7, 331-342 (2012).
2. Ajjan, R., Grant, P. J. Coagulation and atherothrombotic disease. Atherosclerosis 186, 240-59 (2006).
3. Neergaard-Petersen, S. et al. Fibrin clot structure and platelet aggregation in patients with aspirin treatment failure. PLoS One 8, e71150 (2013).
4. Christensen, L., Clemmensen, I. Tetranectin immunoreactivity in normal human tissues. An immunohistochemical study of exocrine epithelia and mesenchyme. Histochemistry 92, 29-35 (1989).
5. Iba, K. et al. Impaired cutaneous wound healing in mice lacking tetranectin. Wound Repair Regen 17, 108-12 (2009).
6. Wang, E. S. et al. Tetranectin and apolipoprotein A-I in cerebrospinal fluid as potential biomarkers for Parkinson's disease. Acta Neurol Scand 122, 350-9 (2010).
7. Begum, F. D. et al. Serum tetranectin as a preoperative indicator for postoperative complications in Danish ovarian cancer patients. Gynecol Oncol 117, 446-50 (2010).
8. Arellano-Garcia, M. E. et al. Identification of tetranectin as a potential biomarker for metastatic oral cancer. Int J Mol Sci 11, 3106-21 (2010).
9. Brunner, A. et al. Expression and prognostic significance of Tetranectin in invasive and non-invasive bladder cancer. Virchows Arch 450, 659-64 (2007).
10. Wang, L. et al. Tetranectin is a potential biomarker in cerebrospinal fluid and serum of patients with epilepsy. Clin Chim Acta 411, 581-3 (2010).
11. Yin, X. et al. Protein biomarkers of new-onset cardiovascular disease: prospective study from the systems approach to biomarker research in cardiovascular disease initiative. Arterioscler Thromb Vasc Biol 34, 939-45 (2014).
12. Kamper, E. F. et al. Tetranectin levels in patients with acute myocardial infarction and their alterations during thrombolytic treatment. Ann Clin Biochem 35 (Pt 3), 400-7 (1998).
13. Fraker, T. D. Jr. et al. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. J Am Coll Cardiol 50, 2264-74 (2007).
14. Lu, L. et al. Reduced serum levels of vasostatin-2, an anti-inflammatory peptide derived from chromogranin A, are associated with the presence and severity of coronary artery disease. Eur Heart J 33, 2297-306 (2012).
15. Tuttolomondo, A. et al. Atherosclerosis as an inflammatory disease. Curr Pharm Des 18, 4266-88 (2012).
16. Han, H. et al. p-Cresyl Sulfate Aggravates Cardiac Dysfunction Associated With Chronic Kidney Disease by Enhancing Apoptosis of Cardiomyocytes. J Am Heart Assoc 4 (2015).
17. ten Cate, H., Lowe, G. Coagulation proteases and cardiovascular disease. Thromb Haemost 112, 858-9 (2014).
18. Iba, K. et al. Delayed fracture healing in tetranectin-deficient mice. J Bone Miner Metab 31, 399-408 (2013).
19. de Vries, T. J., van Muijen, G. N., Ruiter, D. J. The plasminogen activation system in melanoma cell lines and in melanocytic lesions. Melanoma Res 6, 79-88 (1996).
20. Winckers, K., ten Cate, H., Hackeng, T. M. The role of tissue factor pathway inhibitor in atherosclerosis and arterial thrombosis. Blood Rev 27, 119-32 (2013).
21. Nording, H. M., Seizer, P., Langer, H. F. Platelets in inflammation and atherogenesis. Front Immunol 6, 98 (2015).
22. Begum, F. D. et al. Serum tetranectin is a significant prognostic marker in ovarian cancer patients. Acta Obstet Gynecol Scand 89, 190-8 (2010).
23. Nielsen, B. B. et al. Crystal structure of tetranectin, a trimeric plasminogen-binding protein with an alpha-helical coiled coil. FEBS Lett 412, 388-96 (1997).
24. Kluft, C., Jie, A. F., Los, P., de Wit, E., Havekes, L. Functional analogy between lipoprotein(a) and plasminogen in the binding to the kringle 4 binding protein, tetranectin. Biochem Biophys Res Commun 161, 427-33 (1989).
25. Wang, E. S. et al. Tetranectin knockout mice develop features of Parkinson disease. Cell Physiol Biochem 34, 277-87 (2014).
26. Carmena, R., Duriez, P., Fruchart, J. C. Atherogenic lipoprotein particles in atherosclerosis. Circulation 109, III2-7 (2004).
27. Gries, A. Lipoprotein (a)-An Overview. (2012).